

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Otsuki, et al.
Appl. No. : 10/785,446
Filed : February 23, 2004
For : METHOD OF TREATMENT OF
DISEASE USING AN
ADENOSINE A1 RECEPTOR
ANTAGONIST
Examiner : Royds, Leslie A.
Group Art Unit : 1614

CERTIFICATE OF EFS WEB
TRANSMISSION

I hereby certify that this correspondence, and any other attachment noted on the automated Acknowledgement Receipt, is being transmitted from within the Pacific Time zone to the Commissioner for Patents via the EFS Web server on:

November 21, 2007

(Date)


Ned A. Israelsen, Reg. No. 29,653

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

In Response to the Restriction Requirement mailed June 22, 2007, Applicants provisionally elect to prosecute claims directed to Group (II): methods for treating a cardiovascular disease comprising administration of an AA₁RA and a beta blocker. Applicants also elect heart failure as a species of cardiovascular disease, KW-3902 as a species of AA₁RA, and carvedilol as a species of beta blocker. Claims that read on this species include Claims 10-13, and new Claims 26-34. Applicants respectfully request consideration of the following remarks.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.